Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B49 pembrolizumab plus chemotherapy in PD-L1-positive HR+/HER2- advanced breast cancer
jRCT2051210049Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Progression-free survival. Started Jan 2022; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2051210049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210049.